Drug Profile
DIR therapy - Solis Therapeutics
Latest Information Update: 02 Sep 2002
Price :
$50
*
At a glance
- Originator Nonindustrial source
- Developer Nonindustrial source; Solis Therapeutics
- Class
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Viral infections
Most Recent Events
- 02 Sep 1999 Preclinical development for Viral infections in USA (Unknown route)